Inhibition of G6PD has emerged as a potential therapeutic strategy for cancer treatment, such as the application of the small molecule G6PD inhibitor RRX-001 in colorectal cancer and hepatoma cells [16–18], and the endogenous G6PD inhibitor dehydroepiandrosterone (DHEA: 5-androsten-3beta-ol-17-one) in cervical and breast cancer cells [19, 20]. This evidence concerns the gene G6PD and breast cancer.